First-line treatment in advanced non-small-cell lung cancer: The emerging role of the histologic subtype

Marcello Tiseo, Marco Bartolotti, Francesco Gelsomino, Andrea Ardizzoni

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

Lung cancer is the leading cause of cancer mortality worldwide. During the past quarter of a century, there have been definite steps forward in understanding the biology of this disease. However, progress in the treatment of advanced non-small-cell lung cancer (NSCLC) has been more elusive and has not been associated with a realistic probability of long-term survival. For this disease, platinum-based chemotherapy is currently the standard treatment. Numerous studies have compared various platinum doublets and have concluded that all such combinations are comparable in their clinical efficacy. Moreover, several trials evaluating different chemotherapy regimens in NSCLC have failed to document a difference based on histology. Recent evidence suggests that histology represents an important variable in the decision making. This review will discuss this new evidence in the first-line treatment of advanced NSCLC, focusing on different possible therapeutic approaches according to histologic subtype.

Original languageEnglish
Pages (from-to)425-435
Number of pages11
JournalExpert Review of Anticancer Therapy
Volume9
Issue number4
DOIs
Publication statusPublished - 2009

Fingerprint

Non-Small Cell Lung Carcinoma
Platinum
Histology
Drug Therapy
Therapeutics
Lung Neoplasms
Decision Making
Mortality
Neoplasms

Keywords

  • Adenocarcinoma
  • Bevacizumab
  • Cetuximab
  • Non-small-cell lung cancer
  • Pemetrexed
  • Squamous cell carcinoma

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Oncology

Cite this

First-line treatment in advanced non-small-cell lung cancer : The emerging role of the histologic subtype. / Tiseo, Marcello; Bartolotti, Marco; Gelsomino, Francesco; Ardizzoni, Andrea.

In: Expert Review of Anticancer Therapy, Vol. 9, No. 4, 2009, p. 425-435.

Research output: Contribution to journalArticle

Tiseo, Marcello ; Bartolotti, Marco ; Gelsomino, Francesco ; Ardizzoni, Andrea. / First-line treatment in advanced non-small-cell lung cancer : The emerging role of the histologic subtype. In: Expert Review of Anticancer Therapy. 2009 ; Vol. 9, No. 4. pp. 425-435.
@article{0608ad8696624cd7a94af579a8ab54f8,
title = "First-line treatment in advanced non-small-cell lung cancer: The emerging role of the histologic subtype",
abstract = "Lung cancer is the leading cause of cancer mortality worldwide. During the past quarter of a century, there have been definite steps forward in understanding the biology of this disease. However, progress in the treatment of advanced non-small-cell lung cancer (NSCLC) has been more elusive and has not been associated with a realistic probability of long-term survival. For this disease, platinum-based chemotherapy is currently the standard treatment. Numerous studies have compared various platinum doublets and have concluded that all such combinations are comparable in their clinical efficacy. Moreover, several trials evaluating different chemotherapy regimens in NSCLC have failed to document a difference based on histology. Recent evidence suggests that histology represents an important variable in the decision making. This review will discuss this new evidence in the first-line treatment of advanced NSCLC, focusing on different possible therapeutic approaches according to histologic subtype.",
keywords = "Adenocarcinoma, Bevacizumab, Cetuximab, Non-small-cell lung cancer, Pemetrexed, Squamous cell carcinoma",
author = "Marcello Tiseo and Marco Bartolotti and Francesco Gelsomino and Andrea Ardizzoni",
year = "2009",
doi = "10.1586/ERA.09.3",
language = "English",
volume = "9",
pages = "425--435",
journal = "Expert Review of Molecular Diagnostics",
issn = "1473-7159",
publisher = "Expert Reviews Ltd.",
number = "4",

}

TY - JOUR

T1 - First-line treatment in advanced non-small-cell lung cancer

T2 - The emerging role of the histologic subtype

AU - Tiseo, Marcello

AU - Bartolotti, Marco

AU - Gelsomino, Francesco

AU - Ardizzoni, Andrea

PY - 2009

Y1 - 2009

N2 - Lung cancer is the leading cause of cancer mortality worldwide. During the past quarter of a century, there have been definite steps forward in understanding the biology of this disease. However, progress in the treatment of advanced non-small-cell lung cancer (NSCLC) has been more elusive and has not been associated with a realistic probability of long-term survival. For this disease, platinum-based chemotherapy is currently the standard treatment. Numerous studies have compared various platinum doublets and have concluded that all such combinations are comparable in their clinical efficacy. Moreover, several trials evaluating different chemotherapy regimens in NSCLC have failed to document a difference based on histology. Recent evidence suggests that histology represents an important variable in the decision making. This review will discuss this new evidence in the first-line treatment of advanced NSCLC, focusing on different possible therapeutic approaches according to histologic subtype.

AB - Lung cancer is the leading cause of cancer mortality worldwide. During the past quarter of a century, there have been definite steps forward in understanding the biology of this disease. However, progress in the treatment of advanced non-small-cell lung cancer (NSCLC) has been more elusive and has not been associated with a realistic probability of long-term survival. For this disease, platinum-based chemotherapy is currently the standard treatment. Numerous studies have compared various platinum doublets and have concluded that all such combinations are comparable in their clinical efficacy. Moreover, several trials evaluating different chemotherapy regimens in NSCLC have failed to document a difference based on histology. Recent evidence suggests that histology represents an important variable in the decision making. This review will discuss this new evidence in the first-line treatment of advanced NSCLC, focusing on different possible therapeutic approaches according to histologic subtype.

KW - Adenocarcinoma

KW - Bevacizumab

KW - Cetuximab

KW - Non-small-cell lung cancer

KW - Pemetrexed

KW - Squamous cell carcinoma

UR - http://www.scopus.com/inward/record.url?scp=67650330459&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67650330459&partnerID=8YFLogxK

U2 - 10.1586/ERA.09.3

DO - 10.1586/ERA.09.3

M3 - Article

C2 - 19374597

AN - SCOPUS:67650330459

VL - 9

SP - 425

EP - 435

JO - Expert Review of Molecular Diagnostics

JF - Expert Review of Molecular Diagnostics

SN - 1473-7159

IS - 4

ER -